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Abstract
Background: T1 mapping and extracellular volume (ECV) have the potential to guide patient care and serve as
surrogate end-points in clinical trials, but measurements differ between cardiovascular magnetic resonance (CMR)
scanners and pulse sequences. To help deliver T1 mapping to global clinical care, we developed a phantom-based
quality assurance (QA) system for verification of measurement stability over time at individual sites, with further
aims of generalization of results across sites, vendor systems, software versions and imaging sequences. We thus
created T1MES: The T1 Mapping and ECV Standardization Program.
Methods: A design collaboration consisting of a specialist MRI small-medium enterprise, clinicians, physicists and national
metrology institutes was formed. A phantom was designed covering clinically relevant ranges of T1 and T2 in blood and
myocardium, pre and post-contrast, for 1.5 T and 3 T. Reproducible mass manufacture was established. The device
received regulatory clearance by the Food and Drug Administration (FDA) and Conformité Européene (CE) marking.
Results: The T1MES phantom is an agarose gel-based phantom using nickel chloride as the paramagnetic relaxation
modifier. It was reproducibly specified and mass-produced with a rigorously repeatable process. Each phantom contains
nine differently-doped agarose gel tubes embedded in a gel/beads matrix. Phantoms were free of air bubbles and
susceptibility artifacts at both field strengths and T1 maps were free from off-resonance artifacts. The incorporation of
high-density polyethylene beads in the main gel fill was effective at flattening the B1 field. T1 and T2 values measured in
T1MES showed coefficients of variation of 1 % or less between repeat scans indicating good short-term reproducibility.
Temperature dependency experiments confirmed that over the range 15–30 °C the short-T1 tubes were more stable
with temperature than the long-T1 tubes. A batch of 69 phantoms was mass-produced with random sampling of ten
of these showing coefficients of variations for T1 of 0.64 ± 0.45 % and 0.49 ± 0.34 % at 1.5 T and 3 T respectively.
(Continued on next page)
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Conclusion: The T1MES program has developed a T1 mapping phantom to CE/FDA manufacturing standards. An
initial 69 phantoms with a multi-vendor user manual are now being scanned fortnightly in centers worldwide. Future
results will explore T1 mapping sequences, platform performance, stability and the potential for standardization.
Keywords: T1 mapping, Standardization, Phantom,
Background
Myocardial tissue characterisation by T1 mapping and
estimation of extracellular volume (ECV) by cardiovas-
cular magnetic resonance (CMR) is playing an increas-
ingly important role in the diagnosis and management
of patients and clinical trials [1]. T1 mapping is available
as three broad classes of sequences, on multiple plat-
forms, at two field strengths. Factors influencing T1
mapping stability and inter-sequence comparisons are
well understood [1–4] but little is known about T1 map-
ping delivery at a larger scale over many sites and there
is no global quality assurance (QA) system.
The goal of the T1MES program (T1 Mapping and
Extracellular volume Standardisation) was to con-
struct an optimised phantom for QA of myocardial
T1 mapping, covering a relevant range of T1 values
with suitable T2 values for the tissues modelled. The
proposed QA consists of regular scans using fixed
T1-mapping protocols identical to whatever fixed pro-
tocols are used in vivo at each participating site. We
therefore aimed for a phantom design that would
have stable T1 values for as long as possible. We also
aimed for a phantom design avoiding temperature
sensitivity of its T1 values as explained later in
Methods.
Such a QA system would form part of a system for
optimal mapping precision and accuracy [2] within the
increasingly known fundamental limitations of the T1
mapping methods [5, 6].
The T1 Mapping and ECV Standardization (T1MES)
program therefore aimed to:
1. Create a partnership of physicists, clinicians and
national metrology institutes
2. Design phantom systems for 1.5 T and 3 T for any
manufacturer/sequence reflecting T1 values in
myocardium and blood, pre- and post-Gadolinium-
based contrast agents (GBCA)
3. Reproducibly specify and mass produce phantoms
with a rigorously repeatable process and to
regulatory standards
4. Distribute them to global CMR sites with detailed
instructions for fortnightly scanning
5. Publish full details of the formulation to encourage
additional applications
6. Measure confounders (e.g. temperature dependency)
7. Analyse scans over 1 year to study the stability of T1
measurements over time at each scanner, including a
temperature correction model for T1
8. Curate phantom data long-term in an open access
repository available for reuse/analysis
9. Analyse the inter-site differences in T1 values and
explore the deliverability of a technique-independent
‘T1/ECV Standard’ through local calibration
To date we have achieved steps 1 to 6 of this process,
namely the development, testing, certification, QA
protocol and preliminary results of T1MES. This paper
summarises these first 6 milestones.
Methods
Definitions
The term “phantom” refers to the complete test object
(Fig. 1).
The term “tube” refers to each of the small bottles
embedded within the phantom.
The “gel matrix” is the gel and bead mixture filling the
phantom that surrounds all of the tubes.
Collaboration process
A design collaboration for developing and testing the
T1MES phantom and its prototypes was established,
consisting of clinicians, physicists, national metrology
institutes (the US National Institute of Standards and
Technology [NIST] and the German Physikalisch-
Technische Bundesanstalt [PTB]) and a small-medium
enterprise familiar with phantom production (Resonance
Health [RH], Perth, Australia). Funding was secured
including a grant from the European Association of
Cardiovascular Imaging. Time and expertise was pro-
vided for free by the partnership. To engage a global
community with constrained funding, the phantoms
were gifted (first come, first served) to centers with the
proviso that they: a) scan them fortnightly for 1 year and
upload the results; b) engage with the partnership to ex-
plore any unexpected results; c) do not do anything that
could potentially compromise (a) or (b) (e.g. deconstruct
the phantom object); and d) give proper reference to the
T1MES project if they use the phantoms for other
purposes.
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Phantom design
The design process involved several prototype iterations
(known as models A—D before the final mass-production
of E-models). Some aspects such as artefacts from the
prototype A through D-models that guided the final E-
model design are described in Methods and in Fig. 2 with
a timeline in Fig. 3. At the very least, the initial A-D
models were needed to achieve reasonable T1 and T2
values without deleterious imaging artefacts, especially as
imaging was conducted remotely from the manufacturer.
The range of T1 and T2 values in the phantom aims to
cover typical native and post-GBCA values in both myo-
cardium and blood. The especially wide range of T1
post-GBCA (due to variable practice regarding dose,
wash-out delays etc. and of course also disease) requires
several tubes to cover it. From a review of published
values and our own experience, we selected the values
listed. Whatever rationale is adopted, with a limited
number of tubes there will inevitably be gaps.
T1 is generally longer at 3 T compared to 1.5 T. Ini-
tially we aimed to design a single phantom for both
1.5 T and 3 T, containing a sufficient number of tubes to
cover the needed T1 ranges in blood and myocardium,
with suitable T2 values, pre and post-GBCA at both field
strengths. However, the frequency dispersion (i.e. B0 field
dependence) of relaxation times in the phantoms dif-
fered strongly from that of myocardium and blood, par-
ticularly for the long pre-GBCA tubes, requiring a total
of 13 different tubes for 1.5 T and 3 T. Fitting 13 tubes
into a single phantom would either have made the object
‘large’ (in relation to the B1 distortion at 3 T discussed
below) or would have required the use of smaller calibre
tubes. The following considerations justify our construc-
tion therefore of ‘field-specific’ phantoms:
– Tubes had to be a minimum of 20 mm diameter so
regions of interest (arbitrarily set to13 mm) would
exclude in-plane imaging artifacts at the boundaries
between tubes related to the use of clinical T1
mapping protocols with coarse image resolution,
mostly based on single-shot imaging (e.g. Gibbs
artifact at the edge of tubes [Fig. 2d] or the potential
impact of filtering against it applied differently by
various protocol parameters). Altering protocols to
optimise phantom scanning would be inconsistent
with the aim of the project. The true resolution
achieved is further convoluted by the use of
asymmetric frequency-encoded readouts for
faster repetition time (TR) in balanced steady-state
free precession (bSSFP) imaging or partial-phase-
encode sampling for shorter total shot duration,
and to some extent also by signal variation during
the shot.
– Embedding tubes into a gel-filled phantom is
important for three reasons: 1) to permit sufficient
signal for scanner calibrations; 2) to minimise B0
Fig. 1 Internal and external phantom structure. Internal (3 T, looking at the front—a) and external (1.5 T, front and back—b) T1MES phantom
structure. The nine tubes are supported on a translucent resin base composed of unsaturated polyester/styrene. A careful hardening and curing
process ensured a smooth surface finish for the resin base. The front of the phantom (b left) contains an isocenter cross label to aid positioning
as well as an LCD thermometer. Careful positioning of the bottle on the scanner table (c) with the cap towards its head end is needed to ensure
it is scanned at isocenter each time. HDPE = high-density polyethylene; LCD = liquid crystal display; NiCl2 = Nickel Chloride; PE = polyethylene;
PVC = poly vinyl chloride
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and B1 field distortions local to each tube; and 3) for
greater thermal stability. However, embedding all the
13 tubes (to cover 1.5 T and 3 T values) into a single
phantom (whether water or water-based
gel-filled) will have increased its overall dimensions
making it harder to make (our tests and others
[7, 8] show that B1 homogeneity across large ROIs
could not be achieved especially at 3 T). Alternative
oil-based phantoms have a smaller dielectric
permittivity, useful for weaker radiofrequency (RF)
displacement current distortion of B1, but the
chemical shift of the matrix fill would require
embedded tubes also to use oil-based chemistry (as in
diffusion phantoms). Alkanes or similar [9] could not
deliver the required range of T1 and T2 (written as
T1|T2) and a predominately single-peak nuclear mag-
netic resonance (NMR) spectrum, with the required
temperature stability. By using separate water-based
gel-filled phantoms for 1.5 T and 3 T with the known
high permittivity of water, at a size large enough to fit
the needed tubes there was still significant B1 distor-
tion (range of different flip angles achieved for a pre-
scribed protocol nominal flip-angle) but we were able
to counteract it using a method described later.
Fig. 2 Artifact examples in earlier prototypes (a-g) and final T1MES phantom (i, j). Four earlier prototypes (models A—D) were rejected before
the final model. a Coronal image of the earlier A-model (aqueous fill) showing bright artifacts around the tubes resulting from bSSFP going
off-resonance that would have led to variations in T1 values by MOLLI and similar sequences. b Transverse image of A-model showing the
characteristic ‘cat’s head’ artifact of air-bubbles trapped in the paramagnetically doped aqueous tubes. Significant off-resonance artifact is also
noticeable in the central tubes. c Another coronal image through A-model but with larger gaps between tubes showing the combined effect of
motion artifact (due to the aqueous fill) and B0 distortion. d Transverse image of C-model attempting to use narrower tubes to pack 12 instead of
9, but significant Gibbs artifact can be seen in each tube. e Transverse image of C-model showing three small dark circular artifacts (12, 3 and 9
o’clock positions) caused by glue used to stabilize the tube arrangement. We subsequently switched to silicone-based glues that were less likely
to trap air bubbles and were artifact-free. f Severe stabilisation artifact appearing as a thick dark band around the border of a D-model—here the
phantom was scanned immediately after being received from the courier company and the bottle was still very cold from the transportation.
Additionally susceptibility artifacts can be seen as thin linear bands spoiling some of the tubes (9 and 3 o’clock). g Significant image intensity
inhomogeneity during a D-model test session on a GE scanner caused by accidental omission of the folded blanket, intended to separate the
phantom bottle from the anterior chest coil. h Curved tube artifact and dark rings arising from ink printed onto the sides of digestive tubes
(images courtesy of K. E. Keenan and NIST). i Coronal bSSFP localiser image and (j) typical T1 map of a final 3 T T1MES phantom obtained by
MOLLI using a bSSFP readout on a Siemens 3 T Skyra scanner. bSSFP = balanced steady-state free precession; MOLLI = modified Look-Locker
inversion recovery. Other abbreviation as in Fig. 1
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– This project aims to provide quality assurance for
clinically used T1 protocols without adapting to the
phantom (e.g. no switching to spoiled-gradient echo,
or using shorter-TR, no alterations of resolution or
field of view etc.; see Additional file 1). Clinical T1
mapping protocols are sensitive to off-resonance
effects for various well-known reasons. Therefore,
B0distortion near any of the tubes needed
to be minimised (tests showed how tube
alignment with the B0 direction was best—this
data not shown).
Phantom materials
All materials proposed for phantoms to date suffer
different deficiencies. We adopted the most suitable for-
mulation known, which are paramagnetically doped
agarose or carrageenan gels [10, 11]. Some of the main
design aspects are listed in Table 1.
Agarose or similar gel phantoms are widely used in
MR research but less often in commercial phantoms,
probably because of long-term stability issues discussed
later. Gels permit independent variation of T1|T2 and
they avoid fluid movement within image slice during
long inversion recovery (IR) times that could potentially
introduce uncertainty in the T1* to T1 conversion [12].
A more concentrated gelling agent mainly shortens T2; a
higher paramagnetic ion concentration mainly shortens
T1 [11, 13]—the two effects are not independent but can
be modelled [14] enabling design of mixtures with any
required T1|T2 combination. We did not include sodium
chloride (NaCl) (see B1 uniformity section below). Gel
choices include carrageenan, gelatin, agar-agar, polyvinyl
alcohol, silicone, polyacrylamide. Some have undesirable
NMR spectral properties. The paramagnetic ion choice
[15] includes copper, cobalt, iron, manganese (Mn2+),
gadolinium and nickel (Ni2+). Due to the individual
T1|T2 relaxivities of the various ions, no currently
known ionic mixture in water can deliver the native
myocardial T1|T2 combination (which requires a rela-
tively high T1 with a short T2). Ni
2+ was our first choice
as the paramagnetic relaxation modifier at it is less
temperature and frequency dependent than other ions
[13, 16] and because nickel chloride (NiCl2) agarose gel
phantoms have been shown to be stable over a 1 year
period [17].
Characterization of T1 and T2 dependence on agarose and
nickel
To achieve the required T1|T2 tube values we charac-
terised the relation between T1|T2, agarose and NiCl2
concentrations. We made a wide variety of test mixtures
as follows: we dissolved at 95 °C for 2.5 h, 135 different
concentrations of NiCl2, water and agarose, each in a
separate 50 ml digestive tube. Using a preheated sero-
logical pipette, samples were transferred into preheated
NMR tubes (to prevent instant setting of the gel while
flowing down the tube), allowed to set and analysed at a
measuring temperature of 22 °C with a 1.4 T Bruker
Minispec mq60 (60 MHz) relaxometer (Perth, Western
Australia). Exponential fitting was done and T1 and T2
Fig. 3 Prototype models and T1MES project timeline. CE = Conformité Européene; FDA = Food and Drug Administration; GE = General Electric;
NIST = US National Institute of Standards and Technology; PTB = German Physikalisch-Technische Bundesanstalt; QA = quality assurance;
RH = Resonance Health
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recorded. Based on these results we calibrated the
equations [14] modelling the relationship between ingre-
dients and T1|T2 relaxation times (omitting saline). The
model assumes a linear relation between the ingredi-
ents and the relaxation rates (R1,R2) = (1/T1,1/T2).
Using this the ingredients for any required T1|T2 tube
could be calculated. The model was tested for the set
of 13 unique T1|T2 combinations desired for the
1.5 T and 3 T phantoms. Some iterations (models A
through D, Fig. 3) were required to derive from the
model (based on a non-imaging 60 MHz relaxometer)
tube values applicable to clinical 1.5 T and 3 T MR
systems described later.
B0 uniformity
The approximately cuboid, outer body of the T1MES
NiCl2-agarose gel phantom (Fig. 1a) consisted of a short,
hollow, wide necked and leakproof brown-transparent
poly vinyl chloride bottle with a melting temperature of
140 °C (Series #310-73353, Kautex Textron GmbH &
Co. KG, Bonn, Germany). The adopted shape is more
ellipsoidal than many of the shapes rejected in our tests,
consistent with basic magnetostatics (sphere of Lorenz)
at 1.5 T and 3 T. The B0 distortion by the phantom
arises from electronic diamagnetism and is not signifi-
cantly affected by the paramagnetic ion concentrations
used. Adding sufficient paramagnetic material to cancel
Table 1 Design factors when developing a T1 mapping phantom
Design factor Explanation Our proposed solution
Bottle magnetostatics and
B0 distortion
The ideal phantom would be uniform and ellipsoidal
to avoid susceptibility-induced magnetostatic field
perturbation. Such a phantom would permit sphere
of Lorentz uniformity but this is not easily mass
produced. Many phantoms are cylindrical with the
long axis along the static field, B0 but there is usually
off-resonance at the z-ends of such objects [7].
An outer phantom body with a smooth surface and soft
rounded-edges, placed inside B0 still distorts some of the
imposed magnetic field lines at its z-ends so we prescribed
scanning halfway along the length of the bottle.
Long term gel stability
and risk of moulding
Phantoms with long-term stability could assure the
stability of methods applied to patients against
scanner alternations and across multiple centers.
Moulding was prevented by aseptic manufacturing, the
toxicity of Ni2+ ions, and the absence of nutrients in the
type of agarose used. Tap water might contain microbial
contamination and metal ions so high purity water was used.
The main risk is from contraction of gel on loss of water
leading to gaps and water condensation but NiCl2-doped
agarose gel phantoms can be stable over a 1-year period [17].
Seal, leakages, air trapping
for aqueous fill
Air pockets in the agarose gel phantom will give
rise to susceptibility artifacts on account of the large
mismatch in static magnetic susceptibility between
air and surrounding gel producing a local distortion
in magnetic field strength.
The main phantom was sealed by a black polypropylene
screw cap fitted with a polyethylene foam insert. Each
internal digestive tube was sealed by a tight screw cap. Gel
preparation with warm, degassed water reduced air bubble
formation. Note the tube “base-upward” setting procedure
and subsequent “top-up” of the contracted gel in each tube
after setting, described in the text.
Adjustments of B0 and
reference frequency
Adjustments of B0 and scanner reference frequency
over the phantom have the ability to impact T1
estimates.
We specified a constant shim volume for each scan. This is
manufacturer-dependent—see the T1MES manual [23].
Consistency between repeat scans is the main point.
Gel diamagnetism In the T1MES model system, because the impact
of the paramagnetic ions is so small, we can
conceptually treat the main phantom box as if it
had no tubes, as if it were just filled with uniform
gel throughout
The T1MES system has partly paramagnetic and partly
diamagnetic constituents, but the impact of the paramagnetic
Ni2+ ions is small, around 10 % (because concentrations are
small) so the overall interaction is diamagnetic, considering
the ~9 parts per million diamagnetism of most tissues relative
to air from Lenz electronic diamagnetism.
Gibbs artifact ringing and
other inplane effects
Truncating artifacts appear as lines of alternating
brightness and darkness in the read-out and phase
encode direction. Some effects also from
asymmetric readout and ky coverage.
Large diameter digestive tubes to house the 9 agarose doped
solutions, so that central regions of each tube are sufficiently
distant (a number of pixels away) from regions impacted by
artifacts from abrupt signal intensity transitions at the tube
edges.
1.4 T, 1.5 T, 3 T performance Many paramagnetic relaxation modifiers, including
Mn2+ and Cu2+, exhibit significant frequency
dependence.
We used Ni2+[13].
T1|T2 ranges: blood/
myocardium, pre/post-GBCA
The T1|T2 values were carefully modelled for native
and post-gadolinium based contrast agent,
blood and myocardium.
5 common tubes, 4 tubes specific to 1.5 T, 4 tubes specific to
3 T. There was no macromolecular addition (no magnetisation
transfer modelling) [22].
Tube arrangement The phantom corners are more prone to
inhomogeneities of the B0 and B1 magnetic fields.
Longer T1 tubes were placed nearer the middle of the phantom
layout and avoided the corners.
Cu2+ copper ions, Mn2+ manganese ions, Ni2+ nickel ions, NiCl2 nickel chloride
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the diamagnetism and flatten B0 would excessively
shorten the relaxation times.
The final body shape gave sufficient B0 uniformity for
T1 mapping over only a small region approximately half-
way along its length when aligned coaxially with B0.
Regions towards the cap and base of this object were
subject to off-resonance errors [18]. The tubes inside the
phantom were therefore not fixed directly down to the
base of the main bottle. A 20 mm layer of non-coloured
(non-saturated) polystyrene resin (Diggers Casting and
Embedding Resin 500GM, #FIE00506-9311052000759,
Recochem Inc. Perth, Western Australia) was first set
hard in the base of the main bottle, and the tubes were
adhered to the top of this layer, so that the tubes
occupied the middle of the phantom in the cap-to-base
direction, where the B0 field is optimally uniform. B0
uniformity was mapped to evaluate this cause of dis-
torted T1 estimates, using a multi-echo gradient echo
sequence based on the phase difference between known
echo times [19]. A frequency range of +/−50 Hz across
the phantom was regarded as acceptable based on pub-
lished T1-mapping sensitivity to off-resonance [18].
B1 uniformity
B1 uniformity in large water-based phantoms [20, 21] is
complex but fundamentally the electric dipole moment of
the water molecule rotates in the oscillating electric field
associated with the RF B1field, giving rise to displacement
current. Sucrose or other large nonionic molecules can re-
duce water permittivity, by in effect diluting the problem-
atic water molecules. However, the spectral contribution
of such molecules at the high concentrations required is a
severe complication. An alternative approach often de-
scribed in phantom literature is the addition of sodium
chloride or similar simple ionic solutes (n.b. not to be con-
fused with high permittivity of powdered titanates, sus-
pended in deuterated water). This tackles the problem
from a different direction as it leaves the permittivity un-
changed but increases the conductivity (σ) instead, to re-
duce ωε/σ, i.e. the ratio of displacement current to
conduction current. Adding NaCl to the T1MES phantom
acted on B1 distortion at a shallower depth in the T1MES
phantom and did not cancel the overall B1 curvature at
any NaCl concentration tested.
In this work, deriving from the sucrose approach, we
hypothesised that mixing plastic beads into the matrix
gel might also effectively dilute the dielectric permittivity
of water and lead to improved B1 uniformity without
directly altering the outer matrix gel T1|T2 values (see
Table 2, 846 ms |141 ms). Our choice of outer matrix
gel T1|T2 values was informed by tests looking at differ-
ent outer matrix gel T1|T2 combinations (data not
shown) and their impact on bSSFP-stabilisation artifacts
at both field strengths. For the beads, two different kinds
of plastic bead were evaluated: highly monosized microbe-
ads composed of crosslinked poly methyl-methacrylate
(PMMA) polymer (6 μm, Spheromers, Microbeads AS,
Norway) and high-density polyethylene (HDPE) beads of
oblate spheroidal form (3 mm polar axis by 4.2 mm equa-
torial diameter) consisting of smooth, semi-translucent,
colourless HDPE with a melt index >60 °C (HDPE Marlex
HHM 5502 BN, Chevron Phillips Chemical Company LP,
Texas, USA). It is important to control the supply of
HDPE pellets to ensure that they have not been reground,
reblended or otherwise modified. The two different plastic
bead versions of T1MES matrix gel were compared to the
use of sucrose or sodium chloride (formulations tested: (1)
added to 1050 ml of Ni2+-doped gelling solution, separ-
ately and in combination = 800 g sucrose, 50 g NaCl; (2)
added to 1000 ml of distilled water containing NiCl2 and
MnCl2 with T1 ~ 600 ms, T2 ~ 170 ms: 5 g NaCl; (3) added
to 2534 ml of distilled water: 1 g, 4 g, 6.5 g, 11.5 g, 14 g,
19 g, 21.5 g NaCl). B1 homogeneity was evaluated by flip
angle (FA) maps derived by the double angle method
using FA 60° and 120° (θ1, 2*θ1) by long TR (8 s) scanning
using a 4 ms duration sinc (−3π to +3π) slice excitation
width to minimise error due to FA variation through the
slice.
Temperature dependence of T1 and T2
Temperature dependency experiments on T1|T2 values
[15] were carried out at various stages:
Test 1: Performed at the PTB laboratory in June 2015
on a 3 T prototype-D (whole phantom with 9 tubes)
across 17 temperatures between 14.9 °C and 32.0 °C for
T1 and across 6 temperatures between 15.6 °C and
31.1 °C for T2. Each measurement was repeated twice
(with a 2 day gap) and made using a 3 T Siemens
Magnetom Verio system (VB17) and a 12-channel
head coil.
Test 2: Performed at the NIST laboratory in November
2015 on six loose tubes from the final production run
of E-model phantoms. T1|T2 were measured at 9.9,
17.1, 20.1, 23.1 and 30.1 °C on an Agilent 1.5 T small
bore scanner in a temperature-controlled environment.
Temperatures were measured using a fiber optic probe.
T1 was measured by inversion-recovery spin echo
(IRSE) (TR [s] = 10, inversion time [TI, ms] = 50, 75,
100, 125, 150, 250, 500, 1000, 1500, 2000, 3000) and T2
by SE (TR [s] = 10, TE [echo time, ms] = 15, 30, 60,
120, 240, 480, 960). Note that some of the data
acquired under short-term reproducibility was
obtained in support of temperature Test 2.
Short-term reproducibility
Short-term reproducibility (single site, single manufacturer,
single sequence) aided temperature sensitivity work and
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assessed baseline variability between fortnightly scans with
all other parameters constant (not least, temperature). For
the final T1MES phantom (E-model) two short-term
reproducibility experiments were performed:
Test 1: Six loose tubes from the final production
run of E-model phantoms were tested for short-term
reproducibility of T1|T2 values at the NIST laboratory
in November 2015, at 20.1 °C on an Agilent 1.5 T small
bore scanner. T1 was measured by IRSE (TR [s] = 10,
TE [ms] = 14.75, TI [ms] = 50, 75, 100, 125, 150, 250,
500, 1000, 1500, 2000, 3000) and T2 by SE (TR [s] =10,
TE [ms] =14.75, 20, 40, 80, 160).
Test 2: One of the final E-model phantoms for 3 T was
tested for short-term repeatability of T1|T2 values using
a Siemens 3 T Skyra at Royal Brompton Hospital in
November 2015. This test was performed by removing
and repositioning the receiver coil, phantom and its
supports on each of ten runs, incurring full
readjustment of all scanner setup procedures before
each run. The acquired data was ten runs, each
containing two repeated T1 maps, performed at
20.3 ± 0.5 °C. An extension of this work showed that
the temperature increase of the T1MES phantom
caused by specific absorption rate (SAR) deposition
during imaging for repeated T1 maps was negligible.
Detailed construction of phantoms
Some of the detailed construction topics and constraints
are listed in Table 1.
Each phantom (1.5 T or 3 T) contains nine tightly capped
digestive tubes (#SC475, 50 ml from Environmental
Express, South Carolina, USA) embedded in a gel matrix
containing Nickel (II) Chloride hexahydrate (99.9999 %
purity grade, Acros Organics, New Jersey USA, n.b. highly
hygroscopic), high purity deionized water (Ibis Technol-
ogy) and polysaccharide agarose powder with low
endosmotic flow for electrophoresis (molar ra-
tio ≤0.07, Acros Organics).
Mass production was from large batches of 14 solu-
tions (13 tubes + outer matrix gel, Table 2) from which
all the tubes and outer containers were filled accord-
ingly. The mass production required some caution
against deterioration of the agarose/NiCl2 mixtures if
kept at high temperatures for periods exceeding around
8 h. The production of all copies of each tube therefore
had to be completed within a single working day and as
rapidly as possible. Deterioration was noted as a change
of agarose gel colour from colourless to faint yellow.
Microwave oven heating for initial agarose dissolution
was followed by further magnetically-stirred heating and
adjustments (based on relaxometry of samples from the
mixture). Stirring was essential for uniform gel produc-
tion into all copies of each tube. Each of the nine tubes
is filled with differently doped agarose gels and contains
minimal air gaps. Agarose gel contracts as it sets solid,
contracting more in stronger agarose mixtures. By “top-
ping up” more gel to the space left by contraction after
the initial fill had set in each tube, the air gap can be
minimised. Further, by cooling the tubes from the base
(by standing them in approximately 2 cm depth of cold
water), the gel solidified from the base upward so that
contraction left a gap at the top of the tube for adding
the “top-up”. This practical step was essential to avoid
Table 2 List of T1|T2 values for the target 13 tubes and outer matrix gel and the required agarose/NiCl2 concentrations for the final
phantom
Description target (Tube ID) T1 (ms at 1.4 T
a) T2 (ms at 1.4 T
a) Agarose (%) NiCl2 (mM)
“Short” post-GBCA blood (A) 256 172 0.244 5.547
“Normal” native blood 1.5 T (B) 1490 282 0.373 0.362
“Long” post-GBCA blood (C) 427 212 0.325 2.860
“Short” native myocardium 1.5 T (D) 818 54 2.214 1.231
“Long” native myocardium 1.5 T (E) 1384 57 2.279 0.461
“Medium” native myocardium 1.5 T (F) 1107 56 2.256 0.725
“Short” post-GBCA myocardium (G) 295 50 2.174 4.510
“Long” post-GBCA myocardium (H) 557 51 2.377 2.103
“Medium” post-GBCA myocardium (I) 429 50 2.306 2.942
“Normal” native blood 3 T (J) 1870 288 0.388 0.180
“Short” native myocardium 3 T (K) 1043 56 2.245 0.858
“Long” native myocardium 3 T (L) 1510 55 2.289 0.342
“Medium” native myocardium 3 T (M) 1279 56 2.273 0.531
Outer matrix gel fill 846 141 0.780 1.155
aBy Bruker minispec mq60 relaxometer 1.4 T (22 °C) at Resonance Health laboratory, Australia
GBCA gadolinium-based contrast agents, ID identity number
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mid gel contraction gaps forming that is otherwise ob-
served when the gel is allowed to set naturally earlier
along the tube sidewalls. Such mid-gel gaps tend to cause
a tear down the middle of the gel-filled tube making it un-
usable for ROI placement in images. The dissolving and
solidifying temperatures of agarose gel show hysteresis,
dissolving fully only near boiling-point, but requiring cool-
ing to around 45 °C for solidification. The hysteresis
assists practically, for example when pouring molten gel
around the HDPE beads needed for the main matrix fill.
Of the 18 tubes used in the 1.5 T and 3 T phantoms, 4
are 1.5 T specific, 4 are 3 T specific (because tissue na-
tive T1 is longer at 3 T) and five tubes (the post-GBCA
tubes) common to both field strengths (Fig. 4). Although
some difference in post-GBCA T1 values does occur be-
tween 3 T vs. 1.5 T, this difference is absorbed within
the very wide range of GBCA doses, post-GBCA times,
GBCA types etc. in clinical use. Therefore 13 individual
recipes were made. The 9 tubes in each field-specific
phantom generate 9 different T1|T2 combinations (Fig. 5)
modelled to cover the physiological range of native and
post-GBCA, blood and myocardium in health and dis-
ease. There was no macromolecular addition with no at-
tempt to model magnetisation transfer [22].
After pouring in the resin base, leaving this to set, and
adhering the 9 filled tubes on top of this base using
ethylene vinyl acetate and polypropylene uncoloured
mixture based hotmelt typically applied from a “hot glue
Fig. 4 T1 and T2 values in T1MES. T1 and T2 values in the phantom mimic those of myocardium and blood pre and post-GBCA at 1.5 T (Panel a)
and 3 T (Panel b). The 13 relaxometry scopes (refer to Table 2) are explained in the figure. Slow scan reference data for T1|T2 is displayed in green
(for T1 by slow IRSE and for T2 by slow SE, RR interval 900 ms at 21 ± 2 °C), T1 values shown in orange represent the mean value per tube derived
from tests on five of the E-model phantoms (using a 5(3)3 256-matrix RR = 900 ms at 21 ± 2 °C variant of MOLLI adapted for native T1 mapping;
Siemens WIP 448B at 1.5 T and WIP 780B at 3 T), and in blue are T1|T2 values obtained by the manufacturer in Australia using a 1.4 T Bruker
minispec relaxometer at 22 °C. Tube arrangement is such that long T1 tubes potentially suffering from more artifacts are kept towards the middle
of the phantom and away from the corners. GBCA = gadolinium-based contrast agents; IRSE = inversion recovery spin echo; myo =myocardium;
RR = inter-beat interval; SE = spin echo. All T1|T2 values are stated in ms. Other abbreviation as in Fig. 2
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gun”, we packed the compact HDPE pellets into the bot-
tle and then poured in the agarose/NiCl2 mixture (typic-
ally at a temperature ~ 50–60 °C) taking care to avoid air
pockets from forming in the matrix gel fill.
The T1MES phantom has a volume of 2 l, inner length
of 187 mm and inner body cross section 122 mm by
122 mm. The labels show an isocenter cross mark, the
correct orientation for positioning it under an anterior
chest coil, and a serial number and date of manufacture.
Also attached to the outside of the phantom is a liquid
crystal display (LCD) thermometer of 1 °C resolution.
Notably some pigments used on plastic tubes distort the
magnetic field [12] (Fig. 2h), so all components were
tested carefully, rigorously sourced and documented to
avoid unexpected changes which could affect future pro-
duction batches. Even with the efforts to optimise B0
and B1 uniformity, some T1|T2 combinations are more
sensitive to off-resonance errors so these tubes were
placed centrally in the phantom avoiding corner loca-
tions of greater B0/B1 error (explaining the otherwise
somewhat counterintuitive ordering of tubes according
to their T1 values).
Production of one phantom took on average 5 h (dis-
tributed over batch production not serial manufacture).
Fig. 5 T1 and T2 relaxation times versus ingredients at 1.4 T: agarose and NiCl2. Grid represents results of the model. Red points represent single
measurements. a Longitudinal relaxation time constant (T1), RMSE in R1 compared to the linear model was 4.8 × 10
−5 /ms. b Spin–spin relaxation
time (T2), RMSE in R2 compared to the linear model = 5.3 × 10
−4 /ms. Since the x and y axes of both fits are comparable, the ingredient that
contributes most can be identified. RMSE = root mean square error
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As the phantom build was all by manual labour and not
automated, it took 3 weeks and four full-time members,
340 h in total to produce the 69 phantoms in this batch.
Prototype and production batch testing and quality
control
Reproducible manufacturing was established for all tubes.
Three prototypes (models A to C) had unsatisfactory B0
and B1 uniformities before the satisfactory model-D de-
sign. Between June and August 2015, 10 D-model phan-
toms (five for each of 1.5 T and 3 T) were characterized at
ten experienced CMR centers for artifacts and for initial
verification of the tube T1|T2 values. In September 2015,
the final batch of artifact-free (Fig. 2i, j) T1MES phantoms
(E-models) were mass-manufactured and shipped to CMR
centers worldwide.
All aspects of phantom production conducted at the
RH laboratory were performed in accordance with their
certified quality management system including the re-
cruitment and training of staff and the quality control
checks of final phantoms. Prior to the mass manufactur-
ing, extensive experiments were done in order to setup
the standard operation procedures and working instruc-
tions to ensure final phantom integrity. Quality control
was ensured at three levels: operator level (e.g. careful
choice of materials), engineering level (e.g. the respon-
sible process engineer conducted in-production tests/
measurements and inspections, such as checks for bub-
bles in the tubes and bottle seals, and based on the out-
come of this analysis, initiated improvement activities)
and management level (e.g. by facilitating training and
identifying better measurement or production equip-
ment that could be used for future batches). Operator
level quality control evaluated phantoms in real-time
during the production process through visual inspection
to ensure production ran smoothly, predictably, and to
the required standards (e.g. by ensuring a flat resin sur-
face, correctly sealed tubes, tight bead packing of the
outer matrix gel, etc.). Overall phantom integrity was
also visually checked for any production defects prior to
shipment (e.g. precise alignment of isocenter cross label
correctly offset from the upper surface of the resin base,
no distortion of the outer bottle due to excessively hot
gel etc.).
Phantom calibration and validation has limitations as
phantoms do not fully model tissue (see Discussion).
Nonetheless, ‘ground truth’ values in phantoms were
measured using slow scanning ‘gold standard’ sequences
that have previously demonstrated accuracy in phantom
work. Of the 69 final E-model phantoms, 10 (14.5 %; 5
at each of 1.5 T and 3 T) underwent ‘gold standard’ slow
T1 measurements by IRSE (8 TIs from 25–3200 ms) and
T2 measurements by slow SE (8 TEs from 10–640 ms)
at a single center (Royal Brompton Hospital; Siemens,
1.5 T Aera and 3 T Skyra; Fig. 6). These slow T1|T2
measurements were only performed once and the results
used as ‘ground truth’ for the subsequent measurements.
In addition, all tubes were relaxometer-certified pre-
assembly.
Scanning protocol for T1MES
A fundamental aspect of T1MES was to invite each site
to submit phantom data with whichever T1 mapping se-
quence they were using clinically. We did not pre-
specify any aspect of the T1 mapping sequence to use,
except careful replication of position and phantom setup
without any alteration of the parameters used clinically
and not to modify any other parameter of the chosen
protocolled T1 mapping method during the period of
supplying T1MES repeat scans—i.e. to stick to a fixed
protocol (as specified in the JCMR Consensus Guide-
lines for T1/ECV). If changes were inevitable, for ex-
ample due to scanner upgrades, a method of informing
T1MES has been implemented and is described in the
manual (Additional file 1). Instructions for adjustment
and sizing of the shim volume did need to be vendor-
specific and these are explained in the appendix section
of the T1MES user manual circulated to all participants.
At all participating T1MES sites, the final phantom is
currently scheduled for fortnightly scanning for 1 year
using a fixed protocol for inter-scan test-retest analysis.
Some centers are additionally scanning the phantom
using the same sequence at the same position providing
data necessary for short-term intra-scan test–retest ana-
lysis. Results from this longitudinal data collection are
expected to be published in 2017. The T1MES user
manual and QA protocol [23] stipulates that the T1MES
phantom be kept in the MR magnet room (for stability
and also so that its internal temperature will match that
displayed by the surface LCD label) and imaged every
2 weeks for 1 year using consistent coil and phantom
arrangement. The T1MES user manual emphasises that
image parameters be kept unchanged for serial scans ex-
cept for automatic adjustments of FA and reference fre-
quency. The user manual specifies the range of acceptable
positioning of the phantom in the scanner aligned with the
main magnetic field. The phantom is scanned axially half-
way along the length of the 9 internal tubes corresponding
to halfway along the length of the main bottle, imaging
only that slice, to avoid z-end B0 distortion. To ensure con-
sistent adjustments of B0 and scanner reference frequency
over the phantom at each repeat scan, the shim volume
(also referred to as adjustments volume, adjust region,
shim region, shim box) is identically sized and positioned
on the phantom bottle for each scan (see Additional file 1).
The scan protocol is kept identical for serial scans at each
center. Centers were requested to use the same standard
anterior chest coil each time.
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The minimum fortnightly contribution to T1MES con-
sists of conventional CMR scans: A) the initial localizers;
B) at least any one T1 mapping sequence with simulated
electrocardiogram set at 67 beats per minute (inter-beat
[RR] interval 900 ms). The T1MES QA program gener-
ates three main types of multicenter data: 1) raw data
pertaining to long reference scans for T1 (IRSE) and T2
(SE) that we reconstruct on receipt: 2) raw T1 mapping
data from some specific centers without the ability to
reconstruct their own maps locally, thus we reconstruct
the maps on receipt; 3) reconstructed T1|T2 maps
(majority of sites). T1|T2 values were taken as mean
values from circular ROIs of fixed diameter, in each of
the nine tubes in pixel-wise maps.
Within the network are sites using identical magnets,
coils and protocols providing an opportunity for a wide
range of inter-sequence and inter-site analyses (sched-
uled for 2017).
Statistics
Statistical analysis was performed in the R programming
language (version 3.0.1, The R Foundation for Statistical
Computing). Descriptive data are expressed as mean ±
standard deviation except where otherwise stated. Distri-
bution of data was assessed on histograms and using
Shapiro-Wilk test. The coefficient of variation (CoV) be-
tween repeated scans was calculated as a measure of
reproducibility. For defining the model that describes
Fig. 6 Reference T1|T2 values. Variation in the mean T1 (red dots) and T2 (blue dots) reference values and standard deviation (whiskers) of the nine
tubes averaged for the ten final batch T1MES phantoms that underwent ‘gold standard’ slow T1 and T2 measurements by IRSE and SE respectively at
1.5 T (a) and 3 T (b). T1 values obtained by MOLLI (5(3)3 [256] (WIP# 448B at 1.5 T and WIP# 780B at 3 T) pre-GBCA sequence (green dots) are also
shown. Abbreviations as in Figs. 2 and 4
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the relation between ingredients and relaxation rates
(R1|R2), the fitted parameters were found by fitting a
surface for both T1 and T2 using the MATLAB (The
MathWorks Inc., Natick, MA, USA, R2012b) curvefit-
ting tool and the linear least-squares approach. The ana-
lysis of incoming T1MES datasets is carried out using a
MATLAB graphical user interface. From the data, mean
T1 and T2 values were measured from each of the nine
contrast tubes. Using the ROI measurement tool in
MATLAB, mean signal intensity of the central 50 % area
of each of the nine tubes was calculated.
Results
Model predictions of T1 and T2
Linear models for longitudinal and transverse relaxation
rates R1|R2 in terms of the ingredients agarose and NiCl2
can be written following similar work previously pub-
lished [14]:
Rx=ms
−1 ¼ ax þ bx Cw;agarose=%þ cxCNi2þ= mM
where x = 1, 2, Cw,agarose and CNi2þ are the weight and
molar concentration of agarose and Ni2+, respectively,
and ax, bx and cx are found by surface fitting (Fig. 5):
a1 ¼ 3:750 10−4; b1 ¼ 8:790 10−6; c1 ¼ 6:683 10−4
a2 ¼ 1:645 10−4; b2 ¼ 7:622 10−3; c2 ¼ 7:201 10−4
From these relationships and replacing relaxation rate
Rx by relaxation time Tx we calculated the required
agarose % (by weight) and Ni2+ concentrations (equal to
added molar concentration of NiCl2.6H2O as it is highly
dissociated) for each of the 13 tube stock solutions as
shown in Table 2.
The presented model was accurate within the root-
mean-square errors (RMSE) in Fig. 5 caption over the
range T1 = 300–1900 ms and T2 = 40–300 ms that cover
the range of relaxation times expected in healthy and
diseased myocardium pre- and post-GBCA.
Reference T1 and T2 values
Comparison of ‘gold standard’ T1 and T2 values (Fig. 6)
between the ten E-model phantoms tested, confirmed
reproducibility of manufacturing. Across the 9 tubes,
CoV for T1 ranged from 0.17 to 1.25 % at 1.5 T and 0.08
to 1.0 % at 3 T, while T2 ranged from 0.74 to 2.12 % at
1.5 T and 0.40 to 1.72 % at 3 T.
B0 uniformity
Final phantoms were free of air bubbles and susceptibility
artifacts at both field strengths. T1 maps were obtained in
the specified mid-phantom slice at the specified scan setup,
and were free from off-resonance artifacts (Fig. 2i, j). Pro-
vided the bottle was placed coaxial with z-axis, imaged as
a transverse slice halfway along, and with the use of shim-
ming as specified in the T1MES manual, B0 uniformity
was delivered (Fig. 7a) to within ±30 Hz at 3 T.
B1 uniformity
The compact HDPE beads (~1 kg of compact pellets per
phantom bottle) adequately flattened the B1 field at 3 T
(Fig. 7b), compared to the PMMA microbeads, sucrose
and sodium chloride. The HDPE beads cause a speckle
of dark regions in the gel matrix as they generate no MR
signal that is normally detectable. The beads are ex-
pected to have similar diamagnetism to the gel so they
have no impact on the B0 field.
Temperature dependency experiments
Collectively the results (Fig. 8) by slow SE scanning
methods show that over the range 15–30 °C the short-
T1 tubes are more stable with temperature than the
long-T1 tubes where T1 increased more strongly with
temperature. T2 values also change significantly with
temperature (Fig. 8b), decreasing as temperature increases.
Short-term reproducibility
Test 1: Six loose tubes as used in the 1.5 T E-model
(Fig. 9) showed a CoV of ≤1 % for both T1 and T2
reproducibility. Tube B with the longest T1 and T2
showed the greatest variability between repeated scans.
Test 2: Test-retest evaluation of one of the final
phantoms for 3 T by cardiac T1 mapping, including
complete repositioning and readjustments, also gave a
short-term repeatability CoV for T1 ≤1 % (Table 3
detailing results for 3 T). For T2 measured by fast
T2-prepared single-shot methods, the CoV was usually
below 1 % with an exceptionally large 4.1 % in the tube
B with longest T1.
Production, distribution and initiation of trial
On 1st September 2015 the E-model T1MES phantoms
(batch numbers TTP15-001 and TTP30-001 for 1.5 T
and 3 T respectively) received regulatory clearance by
the Food and Drug Administration (FDA) and Con-
formité Européene (CE) marking as a Class I Medical
Device (GMDN 40636). This initial mass manufacturing
phantom experience was not always 100 % successful
and important quality control lessons have been learnt:
for example two different fill solutions for tubes were ac-
cidentally mislabelled initially and had to be discarded
and remade; individual tubes with visible bubbles on
inspection had to be corrected with appropriate proce-
dures; any solution stock with T1 or/and T2 not falling
within +/− 3 % of our pre-specified targeted range had
to be adjusted.
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A total of 75 multi-vendor CMR scanners (four
systems: Siemens, Philips, General Electric [GE] and
Agilent) across five continents (Table 4), are currently
using T1MES phantoms for their local T1 mapping QA
as part of the international T1MES program. This
amounts to an initial 53 individual CMR centers and 69
devices, with six centers using the same field-specific
phantom for QA scans on more than one local machine.
Discussion
Results obtained thus far demonstrate that: 1) mass pro-
duction of phantoms to regulatory standards and in ac-
cordance with a rigorously repeatable process is feasible,
2) based on the sequences used, T1|T2 times in gels are
highly reproducible in the short-term, 3) a significant
temperature dependency of measured T1|T2 values ex-
ists in tubes with longer T1 values that will require the
use of a correction model.
The T1MES program seeks to advance the field of quan-
titative CMR relaxometry and the use of imaging bio-
markers like T1 mapping and ECV in clinical trials and
clinical practice. Our aim was to collaborate with industry,
with leading CMR academics and clinical centers with an
interest in T1 mapping, so as to develop and test a multi-
center QA infrastructure, to protect normal reference data
at centers and also potentially to improve consistency of
T1 mapping and ECV results across imaging plat-
forms, clinical sites, and over time. Key to the
achievement of accurate and reproducible T1mapping/
ECV results in CMR is the accelerated development and
adoption of rigorous hardware and software standards.
However, this proposal is subject to a further limita-
tion that the phantoms do not model other aspects of
tissues, particularly for myocardium—the magnetisa-
tion transfer [22] neither does it address the mapping
techniques’ ability to discriminate T1 values between
adjacent regions of interest (the clinical challenge of
discriminating tissue T1 values in adjacent myocardial
segments). For example, the signal-to-noise ratio in
the phantoms is unrealistically high as the surface
coils are typically nearer; evaluating such an ability is
beyond the scope of T1MES. The only realistic aim
may prove to be that of providing individual (or
genuinely identical) centers with a QA phantom that
could protect normal reference data and assure (or
even permit correction of changes in) stability of pro-
tocols during a long study.
The 1-year study, now running, is expected also to give
information about gel stability. It seems reasonable to
expect sudden steps in T1 values from genuine changes in
the acquisition, or scatter from any remaining uncon-
trolled parameters or imperfect temperature correction,
but there would be a gradual monotonic drift as the gel
water content changes. Agarose gel is inherently unstable
even within a sealed tube, because the gel contracts as
water leaves it, appearing as excess water (as droplets) in
the gap left by the contraction, often visible on the inner
wall of the tube. Note that this effect can occur within
well-sealed tubes. It is unrelated to contamination because
Fig. 7 B0 and B1 field homogeneity. a B0 field homogeneity across
the nine phantom compartments as a measure of off-resonance in
Hz at 3 T (single E-model phantom results). These are extremely
small shifts in frequency (30 Hz = 0.25 ppm) at 3 T and should not
be regarded as significantly different between the tubes. b Diagonal
profile of the B1 field (as per green discontinuous line in the inset)
comparing relative flip angles on a Siemens 3 T system. Variance of
B1 was smallest across the 9 compartments with CoV 1.54 % for
HDPE beads consisting of smooth, semi-translucent, colourless
compact discs (as colouring in plastics has the potential to distort
the B0 magnetic field [12], see Fig. 2h) with a melt index >60 °C. We
choose pellets that had not been regrinded, reblended or composite
for this purpose. Highly monosized microbeads measured 6 μm and
were composed of crosslinked PMMA polymer. Neither microbeads,
sucrose nor NaCl were comparably effective in flattening the B1 field.
PMMA = poly methyl methacrylate. Other abbreviation as in Fig. 4
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agarose without added nutrients does not support mould
growth. Over time, this shrinkage may also occur in the
matrix fill leading to air-gaps and B0 distortion, potentially
occurring near the tubes making a possible contribution
to an apparent drift in T1 values over time. For the first
time, the 1-year study will give large-scale initial data on
the durability of this type of phantom. At study end, we
aim to recall approximately 10 % of the phantoms which
will be inspected for flaws in the gel using high-resolution
3D imaging, with collection also of long reference
T1|T2data as gel drying with shrinkage and condensation
into the gap is known to occur even within a sealed tube.
Centers are free to keep and use the T1MES phantoms
after the 1-year study ends. There is no provision for re-
turn shipment to the coordinating site, nor any knowledge
of how long the gels will remain usable.
The field and temperature dependence of T1 for
phantoms containing Ni2+ is much smaller than those
containing other paramagnetic ions like Cu2+. As T1
increases above 500 ms (in tubes with a low concen-
tration of Ni2+), the tube’s T1 becomes more
temperature-sensitive as it is increasingly dominated
by the temperature sensitive T1 of water in the gel
[24, 25]. Therefore temperature monitoring of each
fortnightly session is essential. Our results enable us
to integrate a temperature-correction model into our
multicenter T1MES analysis, that will be published at
the end of the project. The temperature sensitivity of
T1 revealed in the present work may not be a con-
cern for clinical T1 mapping in healthy volunteers (as
the human body is homeothermic—temperature of
37 °C) but it may be a concern for hypothermic or
febrile patients. Furthermore T2 temperature depend-
ence could also impact measured T1 as some fast-T1
methods have considerable T2 sensitivity.
Conclusion
We report on the establishment of a collaboration to
develop CMR phantoms to CE/FDA standards and an
Fig. 8 Temperature experiments in T1MES. Temperature dependency experiments (Test 1 in methods) performed on a D-model whole phantom
(tube nomenclature differed from that used in E-models) comparing the stability of T1 (a) and T2 (b) values between two repeat experiments
(2 days apart) at various temperatures between 15 °C and 32 °C on a 3 T Siemens Verio system. Whiskers represent mean ± standard error. (c)
Temperature dependency experiment (Test 2 in methods) comparing T1|T2 values in tubes A, B, C, D, E and I (middle right insert) from a final E-model
phantom across five temperatures
Fig. 9 Short-term reproducibility. Short-term reproducibility (three
runs) at the NIST laboratory (Test 1 in methods) for phantom T1values
in six loose tubes (top left insert) from a final E-model phantom
showing CoV of 1 % or less. Tube B with the longest T1|T2 showed the
greatest variability between reads. CoV = coefficient of variation
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initial multicenter repeat scanning program aiming for
global QA of T1 and ECV protocols. A rigorous and re-
producible manufacturing process for the phantoms has
been established. The temperature sensitivity, short-term
stability and inter-phantom consistency have all been
assessed in support of the main project. An initial 69
phantoms with a multi-vendor user manual are now being
scanned fortnightly in centers worldwide, permitting the
academic exploration of T1 mapping sequences, platform
performance and stability over a year.
Table 3 Short-term reproducibility experiments in a 3 T final phantom (E-model)*
Tube Parameter Sequence CoV (%) Mean diff. ± s.d.
A T1 pre_MOLLI_5(3)3_256_T1 0.16 255 ± 0.4
post_MOLLI_4(1)3(1)2_256_MOCO_T1 0.18 255 ± 0.5
T2 T2_4pt_TRUFI_192i_T2 0.66 194 ± 1.3
T2_4pt_GRE_192i_T2 0.61 134 ± 0.8
J T1 pre_MOLLI_5(3)3_256_T1 0.14 1860 ± 2.6
post_MOLLI_4(1)3(1)2_256_MOCO_T1 0.17 1672 ± 2.8
T2 T2_4pt_TRUFI_192i_T2 4.06 227 ± 9.2
T2_4pt_GRE_192i_T2 1.37 203 ± 2.8
C T1 pre_MOLLI_5(3)3_256_T1 0.08 460 ± 0.4
post_MOLLI_4(1)3(1)2_256_MOCO_T1 0.08 461 ± 0.4
T2 T2_4pt_TRUFI_192i_T2 0.52 195 ± 1.0
T2_4pt_GRE_192i_T2 0.76 160 ± 1.2
K T1 pre_MOLLI_5(3)3_256_T1 0.13 953 ± 1.2
post_MOLLI_4(1)3(1)2_256_MOCO_T1 0.10 917 ± 0.9
T2 T2_4pt_TRUFI_192i_T2 0.98 60 ± 0.6
T2_4pt_GRE_192i_T2 0.67 49 ± 0.3
L T1 pre_MOLLI_5(3)3_256_T1 0.08 1372 ± 1.1
post_MOLLI_4(1)3(1)2_256_MOCO_T1 0.16 1252 ± 2.0
T2 T2_4pt_TRUFI_192i_T2 0.91 56 ± 0.5
T2_4pt_GRE_192i_T2 0.89 49 ± 0.4
M T1 pre_MOLLI_5(3)3_256_T1 0.15 1178 ± 1.8
post_MOLLI_4(1)3(1)2_256_MOCO_T1 0.12 1104 ± 1.3
T2 T2_4pt_TRUFI_192i_T2 0.91 58 ± 0.5
T2_4pt_GRE_192i_T2 0.66 49 ± 0.3
G T1 pre_MOLLI_5(3)3_256_T1 0.19 285 ± 0.6
post_MOLLI_4(1)3(1)2_256_MOCO_T1 0.20 285 ± 0.6
T2 T2_4pt_TRUFI_192i_T2 0.29 86 ± 0.2
T2_4pt_GRE_192i_T2 1.02 49 ± 0.5
H T1 pre_MOLLI_5(3)3_256_T1 0.11 527 ± 0.6
post_MOLLI_4(1)3(1)2_256_MOCO_T1 0.09 527 ± 0.5
T2 T2_4pt_TRUFI_192i_T2 0.35 66 ± 0.2
T2_4pt_GRE_192i_T2 0.72 46 ± 0.3
I T1 pre_MOLLI_5(3)3_256_T1 0.06 406 ± 0.3
post_MOLLI_4(1)3(1)2_256_MOCO_T1 0.05 409 ± 0.2
T2 T2_4pt_TRUFI_192i_T2 0.21 72 ± 0.2
T2_4pt_GRE_192i_T2 0.19 47 ± 0.1
*All tests performed at 20.3 ± 0.48 °C on Siemens, Skyra 3 T at RBHT, November 2015 with RR interval 900 ms and using two T1 mapping sequences (pre-MOLLI
5(3)3 [256] and post-MOLLI 4(1)3(1)2 [256] with MOCO, WIPs# 780B) and two T2 mapping sequences (TRUFI T2 map and GRE T2 map)
CoV coefficients of variation, diff. difference, GRE gradient echo, MOCO motion correction, MOLLI modified Look-Locker inversion recovery, RR inter-beat interval,
s.d. standard deviation, TRUFI true fast imaging with steady-state free precession
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Table 4 Quality assurance of T1 mapping: the initial T1MES CMR centers
Center Magnet characteristics
Vendor Tesla Name YOM Software Boreb (cm) Gradient performancec
St Thomas’ Hospital UK Siemens 1.5 Aera 2015 VE11 70 45/200
St Thomas’ Hospital UK Philips 1.5 Ingenia 2013 R4.1.3SP2 70 33/200
Oslo University Hospital Norway Siemens 1.5 Aera 2014 VE11 70 40/200
Bristol Heart Institute UK Siemens 1.5 Avanto 2009 VB17A 60 44/180
Diagnostikum Berlin Germany Siemens 1.5 Aera 2015 VE11 70 45/200
GOSH UK Siemens 1.5 Avanto 2007 VB17 60 40/180
NIH Bethesda US Siemens 1.5 Aera 2014 VE11 70 45/200
Pittsburgh Pennsylvania US Siemens 1.5 Espree 2009 VB17A 70 40/200
Leiden UMC The Netherlands Philips 1.5 Ingenia 2014 R5.1.7SP2 70 45/200
Leeds General Infirmary UK Philips 1.5 Ingenia 2014 R5.1.7SP2 70 45/200
MUMC The Netherlands Philips 1.5 Ingenia 2012 R 5.1.7SP2 70 45/200
Policlinico San Donato Italy Siemens 1.5 Aera 2012 VD13A 70 45/200
Papworth UK Siemens 1.5 Avanto 2008 VB17A 60 50/200
Wythenshawe Manchester UK Siemens 1.5 Avanto 2008 VB17A 60 45/200
Copenhagen University Hospital Denmark Siemens 1.5 Avanto 2008 VD13A 60 45/200
Queen Elizabeth Hospital Birmingham UK Siemens 1.5 Avanto 2008 VB17A 60 33/125
Birmingham Children’s Hospital UK Siemens 1.5 Avanto 2010 VB17A 60 33/125
University of Kentucky USA Siemens 1.5 Aera 2012 VD13A 70 45/200
Charles Perkins Sydney Australia Siemens 1.5 Avanto 2013 VE17A 70 45/200
Taichung Veterans Hospital Taiwan Siemens 1.5 Aera 2005 VE11 60 45/200
Monash Heart Australia Siemens 1.5 Avanto 2010 VB17 55 40/200
Niguarda Hospital Milan Italy Siemens 1.5 Avanto 2005 VB17A 60 40/200
Golden Jubilee Glasgow UK Siemens 1.5 Avanto 2008 VB17A 60 45/200
T-T!ME Multi-center phantoma
INSERM U1044 France Siemens Aera 2012 VD13A 70 40/200
King Abdul-Aziz Saudi Arabia GE 1.5 Discovery MR450 2012 DV24 60 50/200
Prince Charles Hospital Queensland Siemens 1.5 Aera 2011 VD13A 70 45/200
Federal Medical Center Moscow GE 1.5 Optima MR450w 2014 DV25 70 44/200
Medical University of Vienna Austria Siemens 1.5 Avanto 2006 VD13B 60 40/200
DHZ Berlin Germany Philips 1.5 Achieva 2008 R5.1.8 60 33/180
St George’s University London UK Siemens 1.5 Aera 2014 E11 70 45/200
RBHT London UK Siemens 1.5 Avanto 2005 VB17A 60 40/170
University Hospital Southampton UK Siemens 1.5 Avanto 2006 VB17A 60 40/200
Barts Heart Center London UK Siemens 1.5 Aera 2014 VD13A 70 45/200
Barts Heart Center London UK Siemens 1.5 Aera 2015 VE11A 70 45/200
The Heart Hospital London UK Siemens 1.5 Avanto 2009 VD13A 70 40/200
Charité Campus Buch Germany Siemens 1.5 Avanto 2007 VB13B 60 40/200
University of Virginia US Siemens 1.5 Avanto 2005 VB17A 60 45/200
University of Virginia US Siemens 1.5 Avanto 2015 VD13A 60 45/200
SIEMENS EU Siemens 1.5 Aera 2009 VE11 70 45/200
UZ Leuven Belgium Philips 1.5 Ingenia 2007 R5.1.7 60 45/ 200
UZ Leuven Belgium Philips 1.5 Achieva XR 2014 R5.1.7 70 33/122
Beth Israel Deaconess Medical Center, US Philips 1.5 Achieva 2005 R3.2 60 33/180
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Additional file
Additional file 1: The T1MES User Manual. (PDF 13350 kb)
Abbreviations
CE: Conformité Européene; CoV: Coefficients of variation; Cu2+: Copper ions;
DICOM: Digital imaging and communications in medicine; ECV: Extracellular
volume; FA: Flip angle; FDA: Food and Drug Administration;
GBCA: Gadolinium-based contrast agents; GE: General electric; HDPE: High-
density polyethylene; Hz: Hertz; IRSE: Inversion recovery spin echo;
LCD: Liquid crystal display; Mn2+: Manganese ions; MOLLI: Modified look-
locker inversion recovery; MR: Magnetic resonance; NaCl: Sodium chloride;
Ni2+: Nickel ions; NiCl2: Nickel chloride; NMR: Nuclear magnetic resonance;
PMMA: Poly methyl-methacrylate; QA: Quality assurance; R1|R2: Relaxivity of
T1 and T2; RF: Radiofrequency; RMSE: Root-mean-square error; ROI: Region of
interest; RR: Inter-beat interval; SAR: Specific absorption rate;
SASHA: Saturation recovery single-shot acquisition; SE: Spin echo;
ShMOLLI: Shortened modified Look-Locker inversion recovery sequence;
T1|T2: T1 and T2; TE: Echo time; TI: Inversion time; TR: Repetition time
Table 4 Quality assurance of T1 mapping: the initial T1MES CMR centers (Continued)
NIH Bethesda US Siemens 1.5 Aera 2012 VD13A 70 45/200
St Thomas’ Hospital UK Philips 3 Achieva TX 2007 R3.2.3 60 40/200
St Thomas’ Hospital UK Siemens 3 Biograph mMR 2013 VB20P 60 45/200
Fondazione Toscana Monasterio Pisa Italy Philips 3 Ingenia 2012 R5.1.8 70 45/200
Oslo University Hospital Norway Philips 3 Ingenia 2011 5.1.7 70 45/200
Oslo University Hospital Norway Siemens 3 Skyra 2014 VE11 70 45/120
CRIC Bristol UK Siemens 3 Skyra 2009 VD13C 60 44/180
Diagnostikum Berlin Germany Siemens 3 Skyra 2012 VE11 70 45/200
University of Aberdeen Scotland UK Philips 3 Achieva TX 2015 R5.1.7 60 80/100
NIH Bethesda US Siemens 3 Verio 2009 VB17 70 33/125
Leiden UMC The Netherlands Philips 3 Achieva TX 2012 R5.1.8.2 70 45/200
MUMC The Netherlands Philips 3 Achieva TX 2011 R 3.2 60 40/200
Wythenshawe Manchester UK Siemens 3 Skyra 2014 VE11 70 45/200
Copenhagen University Hospital Denmark Siemens 3 Verio 2010 VB17 70 45/200
Charles Perkins Sydney Australia GE 3 Discovery MR750w 2014 DV25 70 44/200
BHF Glasgow Center UK Siemens 3 Prisma 2015 VE11 60 80/200
INSERM U1044 France Siemens 3 Prisma 2015 VE11 60 80/200
DHZ Berlin Germany Philips 3 Ingenia 2011 R5.1.8 70 45/200
St George’s University London UK Philips 3 Achieva TX 2012 R5.1 60 40/150
RBHT London UK Siemens 3 Skyra PTX 2011 VD13C 70 43/180
Barts Heart Center London UK Siemens 3 Prisma 2015 VE11 60 80/200
Leeds General Infirmary UK Philips 3 Achieva TX 2010 R5.2 60 40/120
Montreal Heart Institute Canada Siemens 3 Skyra 2012 VD13A 70 45/200
PTB Germany Siemens 3 Verio 2010 VB17A 70 45/200
University of Virginia US Siemens 3 Skyra 2011 VE11A 70 45/200
UZ Leuven Belgium Philips 3 Ingenia 2010 R5.1.7 70 45/200
NIH Bethesda US Siemens 3 Skyra 2012 VD13A 70 45/200
University of Queensland Australia Siemens 7 Magnetom 7 2013 VB17B 60 72/200
University of Queensland Australia Siemens 3 Trio TIM 2008 VB17A 60 45/200
Glenfield Hospital Leicester UK Siemens 3 Skyra 2010 VD13A 70 45/200
Baker IDI Australia Siemens 3 Prisma 2014 VD13D 60 80/200
NIST USd Agilent 1.5 Varian 2013 VnmrJ 4 14 300/475
NIST USd Agilent 1.5 Varian 2013 VnmrJ 4 14 300/475
aThis phantom is a gift to support the ongoing ’T-T!ME’ study. It will be scanned across multiple UK centers
bInner diameter i.e. around patient
cMaximum gradient performances as returned on the T1MES registration forms by each site. These values are subject to many modifying conditions. More
relevant parameters such as TR and TE will be extracted from uploaded Digital Imaging and Communications in Medicine (DICOM) images where this is possible
from DICOM
dLoose tubes only for 1.5 T and 3 T
YOM year of manufacture
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